SCHEMBL5459964

SCHEMBL5459964

Cc1cc(C(=O)N2CCN(c3ccc4c(c3)CCN(C3CCCC3)CC4)CC2)c(C)o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
LMNA P02545 1/20 0.55
TSHR P16473 1/20 0.55
ACACB O00763 2/20 0.51
ACACA Q13085 2/20 0.51
PKM P14618 1/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPT P10636 3/20 0.47
KDM4E B2RXH2 2/20 0.47
HSD17B10 Q99714 1/20 0.47
HTT P42858 2/20 0.46
TMEM97 Q5BJF2 4/20 0.46
SIGMAR1 Q99720 4/20 0.46
HRH3 Q9Y5N1 2/20 0.46
CHRM4 P08173 1/20 0.46
HTR1A P08908 1/20 0.46
CHRM5 P08912 1/20 0.46
ADRA2A P08913 1/20 0.46
ADRA2B P18089 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5465760 0.80 TSHR (0.50) MEN1KMT2ALMNATSHRALDH1A1
SCHEMBL5457320 0.80 HRH3 (0.44) MEN1KMT2ALMNAALDH1A1TMEM97
SCHEMBL5457085 0.80 TMEM97 (0.52) KMT2ALMNAALDH1A1KDM4EHSD17B10
SCHEMBL5459085 0.79 L3MBTL3 (0.52) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL5465885 0.79 KDM4E (0.60) LMNAALDH1A1KDM4EHTTTMEM97
SCHEMBL5459697 0.79 L3MBTL3 (0.57) ALDH1A1KDM4ETMEM97SIGMAR1HRH3
SCHEMBL5464881 0.78 KDM4E (0.60) ALDH1A1KDM4ETMEM97SIGMAR1HRH3
SCHEMBL5455796 0.78 ATM (0.52) KMT2APKMKDM4ETMEM97SIGMAR1
SCHEMBL5463784 0.78 MGLL (0.47) MEN1KMT2AALDH1A1KDM4ETMEM97
SCHEMBL5461810 0.78 KDM2B (0.53) KMT2ALMNAALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185089-A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders GLAXO GROUP LIMITED (GB) 2007-08-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185089-A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders CNR2, GRIN2C, GRIN2B MEN1 4497/4885KMT2A 390/4885LMNA 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.